Results 161 to 170 of about 6,069,835 (249)
Class IIa HDACs forced degradation allows resensitization of oxaliplatin‐resistant FBXW7‐mutated colorectal cancer
Molecular Oncology, EarlyView.HDAC4 is degraded by the E3 ligase FBXW7. In colorectal cancer, FBXW7 mutations prevent HDAC4 degradation, leading to oxaliplatin resistance. Forced degradation of HDAC4 using a PROTAC compound restores drug sensitivity by resetting the super‐enhancer landscape, reprogramming the epigenetic state of FBXW7‐mutated cells to resemble oxaliplatin ...Vanessa Tolotto, Nicolò Gualandi, Ylenia Cortolezzis, Raffaella Picco, Monica Colitti, Francesca D'Este, Mariachiara Gani, Wayne W. Hancock, Giovanni Terrosu, Cristina Degrassi, Francesca Agostini, Claudio Brancolini, Luigi E. Xodo, Eros Di Giorgio +13 morewiley +1 more sourceLiraglutide Modulates Zinc Release and Improves Mitochondrial Function in Insulin-Resistant Senescent Cardiomyocytes. [PDF]
Cardiovasc ToxicolHosseinpourshirazi F, Mendes UD, Aksoy ZB, Aydos D, Sözer M, Aljaser L, Gundogdu M, Sık S, Tuncay E, Turan B, Olgar Y. +10 moreeuropepmc +1 more sourceIn vitro models of cancer‐associated fibroblast heterogeneity uncover subtype‐specific effects of CRISPR perturbations
Molecular Oncology, EarlyView.Development of therapies targeting cancer‐associated fibroblasts (CAFs) necessitates preclinical model systems that faithfully represent CAF–tumor biology. We established an in vitro coculture system of patient‐derived pancreatic CAFs and tumor cell lines and demonstrated its recapitulation of primary CAF–tumor biology with single‐cell transcriptomics ...Elysia Saputra, Shamsudheen Karuthedath Vellarikkal, Lixia Li, Hong Sun, Khoa Nguyen, Amber Montano, Suchitra Natarajan, Federica Piccioni, Alex Michael Tamburino, Xin Yu, Aleksandra Katarzyna Olow +10 morewiley +1 more sourceResidual lung abnormality following COVID-19 hospitalisation is characterised by biomarkers of epithelial injury. [PDF]
EBioMedicineStewart I, Jacob J, Porter JC, Liu B, Tatler AL, Gomez N, Pugh MR, John AE, Allen RJ, Blaikley JF, Chaudhuri N, Denneny E, Fabbri L, George PM, Guillen-Guio B, Gooptu B, Hall IP, Ho LP, Jarrold I, Johnson S, Jones MG, Khan F, Mehta P, Mitchell J, Molyneaux PL, Pearl JE, Piper Hanley K, Platé M, Quinn V, Rivera-Ortega P, Saunders LC, Smith DJF, Spears M, Spencer LG, Stanel SC, Thompson AAR, Walsh S, Wild JM, Wootton DG, Docherty AB, Gleeson F, Greenhalf W, Harrison EM, Lone N, Quint J, Maslova A, Pohl M, Stephens A, Young S, Singapuri A, Shikotra A, Sereno M, Saunders RM, Richardson M, Raman B, Poinasamy K, McAuley HJC, Marks M, Leavy OC, Houchen-Wolloff L, Horsley A, Harris VC, Greening N, Evans RA, Elneima O, Chalmers JD, Brightling CE, Chambers RC, Wain LV, Jenkins RG, PHOSP-COVID Collaborative Group and the UKILD Consortium. +70 moreeuropepmc +1 more sourceEffect of chemotherapy on passenger mutations in metastatic colorectal cancer
Molecular Oncology, EarlyView.Changes in passenger mutation load and predicted immunotherapy response after chemotherapy treatment. Tumor cells rich with passenger mutations have increased sensitivity to chemotherapy. Correlation of passenger mutations with neoantigen load suggests highly mutated clones promote a more effective response to immunotherapy, and therefore, first‐line ...Marium T. Siddiqui, Matthew A. Cottam, Muhammad Bilal Mirza, Keeli B. Lewis, Kristen K. Ciombor, Mary Kay Washington, Kamran Idrees +6 morewiley +1 more sourceSystematic Evaluation of a Mouse Model of Aging-Associated Parkinson's Disease Induced with MPTP and D-Galactose. [PDF]
Biology (Basel)Liu T, Liu X, Chen Q, Ren J, Li Z, Qiu X, Wang X, Wu L, Hu M, Chen D, Zhang H, Geng X. +11 moreeuropepmc +1 more source